Erythromycin Emerges as a MERS‐CoV Papain‐Like Protease Inhibitor: Unveiling a Dual Mechanism of Thermal Stabilization and Conformational Restriction
Journal of Chemistry · 2026-01 · 2026 (1)
DOI: 10.1155/joch/8866522 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemistry, online erschienen am 07.10.2026. Verfasst von Ahmed L. Alaofi und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University.
Abstract (Originalsprache)
Background
Despite its public health risk and case fatality rate exceeding 35%, there are currently no approved treatments for Middle East Respiratory Syndrome coronavirus (MERS‐CoV). This study investigates the potential of selected antibiotics—erythromycin, linezolid, delafloxacin, and gemifloxacin—as inhibitors of MERS‐CoV papain‐like protease (PLpro), a crucial enzyme for viral replication and immune evasion.
Methods
We assessed the binding and inhibitory effects of four antibiotics on recombinant MERS‐CoV PLpro using thermal shift assays (TSAs), FRET‐based enzyme inhibition assays with a fluorogenic peptide substrate, molecular dynamics (MD) simulations, and MM‐GBSA binding free energy calculations. Dose–response curves were generated to determine IC 50 values, and computational analyses evaluated binding mechanisms and protein conformational changes.
Results
Erythromycin demonstrated notable dose‐dependent inhibition with an IC 50 of 7.089 μM, while other antibiotics showed no significant activity. TSA analysis revealed an exceptional thermal stabilization effect (ΔTm = +19.75°C), confirming strong PLpro binding. MD simulations showed erythromycin stabilizes PLpro while restricting conformational flexibility by 21–43% depending on the metric used. MM‐GBSA calculations yielded a favorable binding free energy (Δ G = −24.19 ± 2.93 kcal/mol), strongly corroborating experimental inhibition data. The binding is driven primarily by van der Waals interactions (−37.46 kcal/mol) through a hydrophobically driven, electrostatically stabilized interface that reduces local flexibility in functional domains.
Conclusions
Erythromycin emerges as a promising candidate for repurposing as a MERS‐CoV antiviral, operating through a unique dual mechanism of enzymatic inhibition and conformational restriction. The strong experimental‐computational agreement validates structure‐based drug repurposing approaches and positions erythromycin for immediate clinical evaluation given its established safety profile and clinically achievable plasma concentrations.
Förderung
- King Saud University
Zitieren
APA
Alaofi, A. L., Shahid, M., Taha, E., & Kalam, M. A. (2026). Erythromycin Emerges as a MERS‐CoV Papain‐Like Protease Inhibitor: Unveiling a Dual Mechanism of Thermal Stabilization and Conformational Restriction. Journal of Chemistry, 2026(1). https://doi.org/10.1155/joch/8866522
Vancouver
Alaofi AL, Shahid M, Taha E, Kalam MA. Erythromycin Emerges as a MERS‐CoV Papain‐Like Protease Inhibitor: Unveiling a Dual Mechanism of Thermal Stabilization and Conformational Restriction. Journal of Chemistry. 2026;2026(1). doi:10.1155/joch/8866522
BibTeX
@article{Alaofi2026,
author = {Alaofi, Ahmed L. and Shahid, Mudassar and Taha, Ehab and Kalam, Mohd Abul},
title = {Erythromycin Emerges as a MERS‐CoV Papain‐Like Protease Inhibitor: Unveiling a Dual Mechanism of Thermal Stabilization and Conformational Restriction},
journal = {Journal of Chemistry},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/joch/8866522}
}
EUVIMED